Related Experiment Videos
Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway
Abstract:
Arsenic has been used as an effective chemotherapy agent for some human cancers, such as acute promyelocytic leukemia. In this study, we found that arsenic induces activation of c-Jun NH2-terminal kinases (JNKs) at a similar dose range for induction of apoptosis in JB6 cells. In addition, we found that arsenic did not induce p53-dependent transactivation. Similarly, there was no difference in apoptosis induction between cells with p53 +/+ or p53 -/-. In contrast, arsenic-induced apoptosis was almost totally blocked by expression of a dominant-negative mutant of JNK1. These results suggest that the activation of JNKs is involved in arsenic-induced apoptosis of JB6 cells. Taken together with previous findings that p53 mutations are involved in approximately 50% of all human cancers and nearly all chemotherapeutic agents kill cancer cells mainly by apoptotic induction, we suggest that arsenic may be a useful agent for the treatment of cancers with p53 mutation.
Insights
Arsenic triggers apoptosis in JB6 cells by activating c-Jun NH2-terminal kinases (JNKs), independent of p53. This suggests arsenic
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Arsenic compounds are utilized in chemotherapy for certain human cancers.
- Apoptosis, or programmed cell death, is a key mechanism for chemotherapeutic agents.
- The role of p53 and c-Jun NH2-terminal kinases (JNKs) in arsenic-induced apoptosis requires further elucidation.
Purpose of the Study:
- To investigate the molecular mechanisms underlying arsenic-induced apoptosis in JB6 cells.
- To determine the involvement of p53 and JNK signaling pathways in arsenic's anti-cancer effects.
Main Methods:
- JB6 cells were treated with arsenic trioxide.
- Assays were performed to measure JNK activation and p53-dependent transactivation.
- Apoptosis induction was assessed in cells with functional or non-functional p53, and in cells expressing a dominant-negative JNK1 mutant.
Main Results:
- Arsenic induced JNK activation and apoptosis in JB6 cells.
- Arsenic-induced apoptosis was independent of p53 status.
- Inhibition of JNK1 activation significantly blocked arsenic-induced apoptosis.
Conclusions:
- JNK activation is a critical mediator of arsenic-induced apoptosis in JB6 cells.
- Arsenic may be a promising chemotherapeutic agent for cancers with p53 mutations.
- Targeting JNK signaling could enhance arsenic's efficacy in cancer treatment.